Keeping Track: RSV Vaccine Race Heats Up Between Pfizer And GSK; Another J&J Bispecific For Myeloma
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
You may also be interested in...
The company had its fourth vaccines day, where it talked about its strategy over the next few years for vaccines against COVID-19, RSV, flu and combinations thereof.
The pharma, which has been de-emphasizing vaccines and infectious disease of late, will end its Phase III trial for an RSV vaccine with May approvals pending for both Pfizer’s and GSK’s candidates.
Novel agents targeting similar indications suggest potential commercial struggles across the therapeutic landscape, with battlegrounds taking shape between RSV vaccines, new mechanisms in major depression, and bispecifics for large B-cell lymphoma.